Cabozantinib D4
| Product Name | Cabozantinib D4 |
|---|---|
| Alternate Names | Cabozantinib Stable Isotopes, Stable Isotopes of Cabozantinib |
| CAT No. | CS-AP-00013 |
| CAS No. | 849217-68-1 (Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 505.53 g/mol |
| Mol. For. | C₂₈H₂₀D₄FN₃O₅ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Cabozantinib |
| Purity | Not less than 90 % |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=C([2H])C([2H])=C(OC4=CC=NC5=C4C=C(OC)C(OC)=C5)C([2H])=C3[2H] |
| Canonical Smiles | COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F |
| InchIKey | ONIQOQHATWINJY-UHFFFAOYSA-N |
| Inchl | InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34) |
| IUPAC | 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Cabozantinib D4 is a deuterated form of Cabozantinib, a small molecule inhibitor used in the treatment of multiple types of cancer. As a tyrosine kinase inhibitor, Cabozantinib D4 targets the VEGFR, MET, and AXL pathways, which are important in the growth and spread of cancer cells. This drug is used in the treatment of various cancers such as medullary thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and others.
The chemical formula of Cabozantinib D4 is C28H18D4FN3O5S, and its molecular weight is 537.62 g/mol. The deuterium atoms in Cabozantinib D4 replace four of the hydrogen atoms present in Cabozantinib, which results in a slight increase in molecular weight and a shift in the mass spectrum. The use of deuterium in the drug molecule can also help in improving its pharmacokinetic properties.
Cabozantinib D4 is available in the form of a capsule for oral administration. The recommended dose and duration of treatment may vary depending on the type and stage of cancer being treated, as well as the patient’s overall health and response to therapy.
As with any medication, Cabozantinib D4 may cause side effects such as fatigue, nausea, diarrhea, and high blood pressure. It is important to discuss any concerns or questions about the use of this drug with a healthcare provider.
Get an Instant Quote
Related Compounds
Cabozantinib-d6 | Cabozantinib D4(FluoroBenzene-ring-d4) |